C4 Imaging develops medical devices that enable clinicians to more accurately perform image-guided procedures. The company’s core proprietary technology, C4, has been developed as the first commercially available Positive-Signal MRI Marker.
With over 25 years of experience in commercial leadership roles in the medical device and life sciences industries, Mr. Bright has been involved in the launch of some of the most successful products in the brachytherapy market in both the US and Europe. He now leads C4 Imaging with the objective of ensuring that the successful commercialization of the company's core MRI technology brings clinical utility to physicians and ultimately improves care for the patients they treat.
Previously, Mr. Bright was Vice President, Global Sales and Marketing, and Vice President, Brachytherapy, at Oncura (A GE Healthcare business). He is an Applied Biology graduate of the University of Greenwich in London, UK.
Dr. Frank is an endowed tenured Professor of Radiation Oncology at the University of Texas MD Anderson Cancer Center (UTMDACC). He is the Deputy Division Head for Strategic Programs and the Executive Director of the UT Particle Therapy Institute. He has recently served the American Brachytherapy Society as both President and Chairman of the Board where he established a strategic plan to 'Bend the Slope of the Brachytherapy Curve'. He serves on the editorial board for the International Journal of Brachytherapy and heads the Prostate Brachytherapy program at MD Anderson where he has pioneered MRI-Assisted Radiosurgery (MARS) as the most advanced form of high-quality prostate brachytherapy. He has served as the quality assurance expert for prostate brachytherapy for national cooperative group clinical trials in prostate brachytherapy funded by the National Institutes of Health and National Cancer Institute, and has served as the quality assurance brachytherapy expert for the MD Anderson Physicians Network.
Dr. Frank has a passion for high-quality education and training and has pioneered a simulation treatment model for prostate brachytherapy using prostate phantoms. He has established international conferences and workshops in prostate brachytherapy and given numerous presentations nationally and internationally providing oversight for the development of brachytherapy programs. He has recognized the problems inherent in the quality of prostate brachytherapy that led to the development of the C4 technology at MD Anderson. He has received extensive peer reviewed funding including the NIH/NCI, Prostate Cancer Foundation, the UTMDACC, and the Texas Ignition Fund.
Dr. Frank is a graduate of the University of Pennsylvania and entered the naval nuclear propulsion program in 1991. He served as a Submarine Officer on the fast-attack nuclear submarine, U.S.S. Batfish (SSN-681), and completed his active duty service in 1996 as a Lieutenant. Dr. Frank earned his medical degree at Emory University School of Medicine in 2000, completed his residency in Radiation Oncology at the University of Texas MD Anderson Cancer Center, and has been on the MD Anderson faculty since 2005. Dr. Frank is the author of more than 200 peer-reviewed scientific publications and a national and international recognized expert in prostate brachytherapy.